On May 14, 2021 IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) ("IntelGenx"), a leader in pharmaceutical films, reported that the previously announced US$12,346,300 investment in IntelGenx by ATAI Life Sciences AG ("atai") has been completed (Press release, IntelGenx, MAY 14, 2021, View Source,atai%E2%80%9D)%20has%20been%20completed.&text=Zerbe%2C%20CEO%20of%20IntelGenx. [SID1234580072]). As a result of the investment, atai now holds approximately 25% of the issued and outstanding common stock of IntelGenx.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We would again like to thank our shareholders for their support of our transformative strategic partnership with atai," said Dr. Horst G. Zerbe, CEO of IntelGenx. "In addition to positioning IntelGenx as a leader within the novel therapeutics field of psychedelics, atai’s investment provides us with the requisite financial resources to continue to advance our portfolio of other pharmaceutical film product candidates towards commercialization."

"We are pleased to have achieved our goal of progressing from collaborators to partners with IntelGenx via this transaction, and we are excited to make IntelGenx’s innovative film technology an integral part of our platform," said Florian Brand, CEO of atai."